Join Growin Stock Community!

順藥6535.TW Overview

TW StockBiotech. & Medical
(No presentation for 6535)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

順藥（6535）Overall Performance

順藥（6535）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

順藥（6535） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

順藥（6535）Key Information

順藥（6535）Profile

Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

順藥（6535）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
61.04%
Net Margin
-950.41%
Revenue Growth (YoY)
-8.49%
Profit Growth (YoY)
23.49%
3-Year Revenue Growth
-3.12%
3-Year Profit Growth
-8.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
61.04%
Net Margin
-950.41%
Revenue Growth (YoY)
-8.49%
Profit Growth (YoY)
23.49%
3-Year Revenue Growth
-3.12%
3-Year Profit Growth
-8.52%
default symbol

6535

順藥

168.00D

-0.60%

(-0.01)

  • When is 6535's latest earnings report released?

    The most recent financial report for 順藥 (6535) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6535's short-term business performance and financial health. For the latest updates on 6535's earnings releases, visit this page regularly.

  • What is the operating profit of 6535?

    According to the latest financial report, 順藥 (6535) reported an Operating Profit of -43.46M with an Operating Margin of -333% this period, representing a growth of 62.31% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6535's revenue growth?

    In the latest financial report, 順藥 (6535) announced revenue of 13.05M, with a Year-Over-Year growth rate of -34.11%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6535 have?

    At the end of the period, 順藥 (6535) held Total Cash and Cash Equivalents of 181.59M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6535 go with three margins increasing?

    In the latest report, 順藥 (6535) did not achieve the “three margins increasing” benchmark, with a gross margin of 56.37%%, operating margin of -333%%, and net margin of -436.81%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6535's profit trajectory and future growth potential.

  • Is 6535's EPS continuing to grow?

    According to the past four quarterly reports, 順藥 (6535)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6535?

    順藥 (6535)'s Free Cash Flow (FCF) for the period is -1.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 99.79% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.